Silence Therapeutics (SLN) Stock Forecast, Price Target & Predictions
SLN Stock Forecast
Silence Therapeutics stock forecast is as follows: an average price target of $52.00 (represents a 661.35% upside from SLN’s last price of $6.83) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
SLN Price Target
The average price target for Silence Therapeutics (SLN) is $52.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $49.00. This represents a potential 661.35% upside from SLN's last price of $6.83.
SLN Analyst Ratings
According to 4 Wall Street analysts, Silence Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SLN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Silence Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Keay Nakae | Chardan Capital | $55.00 | $19.00 | 189.47% | 705.27% |
| Jun 28, 2024 | Michael Ulz | Morgan Stanley | $49.00 | $19.00 | 157.89% | 617.42% |
| Mar 13, 2024 | Kostas Biliouris | BMO Capital | $67.00 | $25.61 | 161.62% | 880.97% |
| Dec 09, 2022 | Morgan Stanley | $18.00 | $15.23 | 18.19% | 163.54% | |
| Nov 17, 2022 | Chardan Capital | $29.00 | $13.21 | 119.53% | 324.60% |
The latest Silence Therapeutics stock forecast, released on Jun 28, 2024 by Keay Nakae from Chardan Capital, set a price target of $55.00, which represents a 189.47% increase from the stock price at the time of the forecast ($19.00), and a 705.27% increase from SLN last price ($6.83).
Silence Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $57.00 |
| Last Closing Price | $6.83 | $6.83 | $6.83 |
| Upside/Downside | -100.00% | -100.00% | 734.55% |
In the current month, the average price target of Silence Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Silence Therapeutics's last price of $6.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 02, 2024 | Jefferies | Buy | Initialise | |
| Aug 16, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Aug 16, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 28, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 20, 2024 | Morgan Stanley | Buy | Buy | Hold |
| May 28, 2024 | BMO Capital | Outperform | Outperform | Hold |
| May 17, 2024 | Morgan Stanley | Buy | Buy | Hold |
| May 17, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Apr 22, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Apr 22, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Mar 14, 2024 | Chardan Capital | Buy | Buy | Hold |
| Mar 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Mar 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 09, 2022 | Morgan Stanley | Equal-Weight | Initialise |
Silence Therapeutics's last stock rating was published by BMO Capital on Dec 02, 2024. The company gave SLN a "Outperform" rating, the same as its previous rate.
Silence Therapeutics Financial Forecast
Silence Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $11.37M | $4.76M | $2.70M | $3.14M |
| Avg Forecast | $3.04M | $2.99M | $2.99M | $3.04M | $6.74M | $4.37M | $9.21M | $5.06M | $7.08M | $2.41M | $3.06M | $2.49M | $16.51M | $2.38M | $1.61M |
| High Forecast | $4.10M | $4.03M | $4.03M | $4.10M | $9.07M | $5.89M | $12.39M | $6.81M | $11.52M | $2.44M | $4.11M | $3.36M | $22.22M | $2.38M | $1.61M |
| Low Forecast | $2.07M | $2.03M | $2.03M | $2.07M | $4.58M | $2.97M | $6.26M | $3.44M | $2.65M | $2.37M | $2.08M | $1.69M | $11.22M | $2.38M | $1.61M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.56% | 0.29% | 1.14% | 1.95% |
Silence Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.06M, with a low forecast of $2.08M, and a high forecast of $4.11M. SLN's average Quarter revenue forecast represents a -73.13% decrease compared to the company's last Quarter revenue of $11.37M (Mar 23).
Silence Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-11.68M | $-14.90M | $-12.59M | $-9.21M |
| Avg Forecast | $-3.04M | $-2.99M | $-2.99M | $-3.04M | $-6.74M | $-4.37M | $-9.21M | $-5.06M | $-7.08M | $-2.41M | $-3.06M | $-2.49M | $-16.51M | $-2.38M | $-1.61M |
| High Forecast | $-2.07M | $-2.03M | $-2.03M | $-2.07M | $-4.58M | $-2.97M | $-6.26M | $-3.44M | $-2.65M | $-2.37M | $-2.08M | $-1.69M | $-11.22M | $-2.38M | $-1.61M |
| Low Forecast | $-4.10M | $-4.03M | $-4.03M | $-4.10M | $-9.07M | $-5.89M | $-12.39M | $-6.81M | $-11.52M | $-2.44M | $-4.11M | $-3.36M | $-22.22M | $-2.38M | $-1.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.68% | 0.90% | 5.30% | 5.72% |
undefined analysts predict SLN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Silence Therapeutics's previous annual EBITDA (undefined) of $NaN.
Silence Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-10.20M | $-13.76M | $-11.63M | $-8.42M |
| Avg Forecast | $-7.88M | $-7.00M | $-6.77M | $-6.25M | $-4.54M | $-4.59M | $-4.16M | $-4.50M | $-2.99M | $-6.47M | $-6.47M | $-5.56M | $-622.04K | $-26.92M | $-27.20M |
| High Forecast | $-4.60M | $-4.08M | $-3.95M | $-3.65M | $-3.93M | $-2.80M | $-2.43M | $-2.63M | $358.29K | $-3.77M | $-3.77M | $-3.24M | $-362.84K | $-26.92M | $-27.20M |
| Low Forecast | $-11.43M | $-10.14M | $-9.80M | $-9.06M | $-5.45M | $-5.64M | $-6.03M | $-6.53M | $-4.90M | $-9.38M | $-9.37M | $-8.06M | $-901.55K | $-26.92M | $-27.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.83% | 22.13% | 0.43% | 0.31% |
Silence Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Silence Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $6.45M | $3.47M | $5.38M | $3.75M |
| Avg Forecast | $27.78M | $27.32M | $27.32M | $27.78M | $61.49M | $39.91M | $84.00M | $46.17M | $64.62M | $21.95M | $27.88M | $22.75M | $150.65M | $21.67M | $14.68M |
| High Forecast | $37.38M | $36.76M | $36.76M | $37.38M | $82.74M | $53.70M | $113.03M | $62.13M | $105.10M | $22.29M | $37.52M | $30.61M | $202.72M | $21.67M | $14.68M |
| Low Forecast | $18.87M | $18.56M | $18.56M | $18.87M | $41.78M | $27.11M | $57.07M | $31.37M | $24.13M | $21.61M | $18.94M | $15.46M | $102.36M | $21.67M | $14.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.28% | 0.02% | 0.25% | 0.26% |
Silence Therapeutics's average Quarter SG&A projection for Jun 23 is $27.88M, based on 1 Wall Street analysts, with a range of $18.94M to $37.52M. The forecast indicates a 332.26% rise compared to SLN last annual SG&A of $6.45M (Mar 23).
Silence Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.43 | $-0.39 | $-0.29 |
| Avg Forecast | $-0.17 | $-0.15 | $-0.14 | $-0.13 | $-0.10 | $-0.10 | $-0.09 | $-0.10 | $-0.06 | $-0.14 | $-0.14 | $-0.12 | $-0.01 | $-0.58 | $-0.58 |
| High Forecast | $-0.10 | $-0.09 | $-0.08 | $-0.08 | $-0.08 | $-0.06 | $-0.05 | $-0.06 | $0.01 | $-0.08 | $-0.08 | $-0.07 | $-0.01 | $-0.58 | $-0.58 |
| Low Forecast | $-0.24 | $-0.22 | $-0.21 | $-0.19 | $-0.12 | $-0.12 | $-0.13 | $-0.14 | $-0.10 | $-0.20 | $-0.20 | $-0.17 | $-0.02 | $-0.58 | $-0.58 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 2.35% | 32.31% | 0.68% | 0.50% |
According to undefined Wall Street analysts, Silence Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLN previous annual EPS of $NaN (undefined).
Silence Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| SLN | Silence Therapeutics | $6.51 | $52.00 | 698.77% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| PRLD | Prelude Therapeutics | $0.89 | $4.00 | 349.44% | Sell |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| APLT | Applied Therapeutics | $1.10 | $4.50 | 309.09% | Buy |
| GNFT | Genfit | $3.66 | $13.00 | 255.19% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| IGMS | IGM Biosciences | $7.48 | $18.67 | 149.60% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| RNA | Avidity Biosciences | $32.74 | $59.00 | 80.21% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| TARS | Tarsus Pharmaceuticals | $53.26 | $63.00 | 18.29% | Buy |
| CDTX | Cidara Therapeutics | $22.81 | $12.00 | -47.39% | Buy |